Teva Pharmaceutical Industries (TEVA) Expected to Post Earnings on Tuesday

Teva Pharmaceutical Industries (NYSE:TEVA) is projected to release its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect Teva Pharmaceutical Industries to post earnings of $0.72 per share and revenue of $4.24 billion for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 8:00 AM ET.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Tuesday, June 30th. The company reported $0.02 EPS for the quarter. The business had revenue of $4.14 billion for the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.64%. On average, analysts expect Teva Pharmaceutical Industries to post $2.00 EPS for the current fiscal year and $3.04 EPS for the next fiscal year.

Teva Pharmaceutical Industries Stock Performance

Teva Pharmaceutical Industries stock opened at $39.93 on Tuesday. The company has a debt-to-equity ratio of 1.56, a quick ratio of 0.67 and a current ratio of 0.88. Teva Pharmaceutical Industries has a fifty-two week low of $19.00 and a fifty-two week high of $42.02. The stock has a fifty day moving average of $38.75 and a two-hundred day moving average of $34.38. The company has a market capitalization of $46.53 billion, a price-to-earnings ratio of 66.54, a PEG ratio of 3.66 and a beta of 0.89.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on TEVA. Leerink Partners initiated coverage on shares of Teva Pharmaceutical Industries in a report on Wednesday, September 9th. They issued an “outperform” rating and a $45.00 target price on the stock. Barclays lifted their price objective on Teva Pharmaceutical Industries from $42.00 to $47.00 and gave the company an “overweight” rating in a research report on Thursday, October 15th. Oppenheimer boosted their price target on Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the company an “outperform” rating in a research report on Friday, October 9th. Zacks Research lowered shares of Teva Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 20th. Finally, JPMorgan Chase & Co. upped their price target on Teva Pharmaceutical Industries from $40.00 to $50.00 and gave the stock an “overweight” rating in a report on Monday, October 12th. Twelve analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $46.08.

Insiders Place Their Bets

In other news, Director Roberto Mignone sold 367,600 shares of the business’s stock in a transaction on Friday, September 18th. The shares were sold at an average price of $39.06, for a total transaction of $14,358,456.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Brian Savage sold 7,342 shares of the stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $38.85, for a total transaction of $285,236.70. Following the completion of the sale, the insider directly owned 8,500 shares in the company, valued at approximately $330,225. This trade represents a 46.35% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 374,959 shares of company stock worth $14,644,285 over the last quarter. 0.54% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. Founded in 1901, the company is one of the world’s largest producers of generic medicines and develops, manufactures and distributes prescription products across a broad range of therapeutic areas.

Teva’s portfolio includes generic medicines, specialty pharmaceuticals, biosimilars, active pharmaceutical ingredients and over-the-counter products. Its specialty medicines include treatments for neurological and movement disorders, respiratory conditions, migraine and other chronic diseases.